| |
HBsAg
|
Anti-HBc
|
Anti-HBs
|
Anti-HBc IgM
|
HBeAg
|
Anti-HBe
|
HBV DNA
|
ALT (IU/L)
|
AST (IU/L)
|
|---|
|
March 2012 (pre-immunization)
|
neg.
|
neg.
|
neg.
| | | | |
63 (H)
|
45 (H)
|
|
November 2012 (post-immunization)
|
pos.a
|
neg.a
|
neg.
| | | |
1.8×109 IU/mL (done a posteriori)
|
(N)
|
(N)
|
|
December 2012
|
pos.a
|
neg.a
|
neg.
| | | | |
56 (H)
|
(N)
|
|
January 2013
|
pos.
|
neg.
|
neg.
| | | | |
(N)
|
(N)
|
|
February 2013
|
pos.
|
neg.
|
neg.
|
neg.
|
pos.
|
neg.
|
3.5×109 IU/mL
|
(N)
|
(N)
|
|
March 2013
|
pos.
|
neg.
|
neg.
| |
pos.
|
neg.
|
2.6×109 IU/mL
|
(N)
|
(N)
|
|
June 2013
|
pos.
|
pos.
|
neg.
| |
pos.
|
neg.
|
2.3×109 IU/mL
|
53 (H)
|
54 (H)
|
|
October 2013
|
pos.
|
pos.
|
neg.
| |
pos.
|
neg.
|
1.8×109 IU/mL
|
81 (H)
|
52 (H)
|
|
January 2014
|
pos.
|
pos.
|
pos. (52.7 IU/L)
| |
pos.
|
neg.
|
5.8×108 IU/mL
|
65 (H)
|
44 (H)
|
|
April 2014
|
pos.
|
pos.
|
pos. (133.5 IU/L)
| |
pos.
|
neg.
|
4.9×108 IU/mL
|
44 (H)
|
34 (H)
|
|
August 2014
|
pos.
|
pos.
|
pos. (247.0 IU/L)
| |
pos.
|
neg.
|
2.9×108 IU/mL
|
43 (H)
|
37 (H)
|
|
December 2014 (tenofovir started in September 2014)
|
pos.
|
pos.
|
pos. (107.4 IU/L)
| |
pos.
|
neg.
|
1.6×105 IU/mL
|
(N)
|
(N)
|
|
March 2015
|
pos.
|
pos.
|
pos. (24.3 IU/L)
| |
pos.
|
neg.
|
5.1×103 IU/mL
|
(N)
|
(N)
|
|
June 2015
|
pos.
|
pos.
|
pos. (27.2 IU/L)
| |
pos.
|
neg.
|
7.2×102 IU/mL
|
(N)
|
(N)
|
|
September 2015
|
pos.
|
pos.
|
pos. (13.8 IU/L)
| |
pos.
|
neg.
|
7.1×102 IU/mL
|
(N)
|
(N)
|
-
Anti-HBe Hepatitis B envelope antibody, ALT alanine aminotransferase, anti-HBc hepatitis B core antibody, anti-HBs hepatitis B surface antibody, AST aspartate aminotransferase, blank no result available, DNA deoxyribonucleic acid, H elevated value, HBeAg Hepatitis B envelope antigen, HBsAg hepatitis B surface antigen, HBV hepatitis B virus, IgM Immunoglobulin M, IU international units, L Litre, mL Millilitre, N normal value, neg. negative, pos. positive
-
aConfirmed with a second assay
